
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Fewer newborns are being born with cystic fibrosis in Massachusetts, a decrease that researchers attribute to increased preconception and prenatal screening for the genetic disease, according to an article published in the Feb. 28 issue of the New England Journal of Medicine.






